We are live on ! Find out more
MPM BioImpact

MPM BioImpact Portfolio holdings

AUM $1.35B Turnover 42.55%
1-Year Est. Return 172.14%
 

MPM BioImpact runs biotech venture, hybrid and hedge funds, and its impact funds put private and public money into companies aiming to change outcomes for patients with disease. Its hedge funds concentrate on small and mid-sized healthcare companies, while the firm as a whole combines MPM Capital's biotech venture capital record of more than 30 years with BioImpact's public investing. The firm was called MPM Oncology Impact Management until 2021 and BioImpact Capital until 2023. Ansbert Gadicke, its founder and managing partner, is also its controlling owner. Among its portfolio stories, it built the radiopharmaceutical company Aktis Oncology for solid tumors and was an early backer of argenx, an immunology company.

This Fund
S&P 500
This Quarter Est. Return
+0.4%
1 Year Est. Return
+172.14%
3 Year Est. Return
+619.29%
5 Year Est. Return
+756.25%
10 Year Est. Return
–
AUM
$549M
AUM Growth
-$96.1M
Cap. Flow
-$15.7M
Cap. Flow %
-2.86%
Top 10 Hldgs %
73.13%
Holding
35
New
2
Increased
2
Reduced
22
Closed
2
Avg Time Held
0.7 years
Top 10 Avg Time Held
0.9 years
Top 20 Avg Time Held
1 year

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
CGEM icon
1
Cullinan Therapeutics
CGEM
$577M
$118M 21.51%
7,648,268
– –
2021 Q1
3 quarters
ITOS icon
2
DELISTED
iTeos Therapeutics
ITOS
$85.9M 15.66%
1,844,727
-262,365
-12% -$8.73M
2020 Q3
5 quarters
RPTX icon
3
DELISTED
Repare Therapeutics
RPTX
$34.6M 6.3%
1,639,849
– –
2020 Q2
6 quarters
LITS icon
4
Lite Strategy
LITS
$24M
$33M 6.01%
+617,549
New +$34.4M
2021 Q4
0 quarters
MRUS icon
5
DELISTED
Merus
MRUS
$29.5M 5.38%
927,302
-14,646
-2% -$414K
2020 Q2
6 quarters
HOWL icon
6
Werewolf Therapeutics
HOWL
$46M
$28.4M 5.19%
2,388,011
– –
2021 Q2
2 quarters
HARP
7
DELISTED
Harpoon Therapeutics
HARP
$24.1M 4.4%
319,671
– –
2019 Q4
8 quarters
NTLA icon
8
Intellia Therapeutics
NTLA
$1.4B
$19M 3.46%
160,527
-2,093
-1% -$262K
2021 Q3
1 quarter
TCRR
9
DELISTED
TCR2 Therapeutics
TCRR
$15.7M 2.86%
3,370,982
– –
2019 Q4
8 quarters
TPTX
10
DELISTED
Turning Point Therapeutics
TPTX
$12.9M 2.36%
271,350
– –
2020 Q1
7 quarters
ONCR
11
DELISTED
Oncorus
ONCR
$12.5M 2.28%
2,377,031
– –
2020 Q4
4 quarters
CRNX icon
12
DELISTED
Crinetics Pharmaceuticals
CRNX
$10.8M 1.97%
379,792
+81,400
+27% +$2.01M
2021 Q3
1 quarter
CYTK icon
13
Cytokinetics
CYTK
$7.07B
$10.6M 1.93%
232,268
-15,023
-6% -$580K
2021 Q3
1 quarter
EPIX icon
14
DELISTED
ESSA Pharma
EPIX
$9.5M 1.73%
668,688
-14,599
-2% -$163K
2021 Q3
1 quarter
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$1.86B
$9.17M 1.67%
661,951
-42,816
-6% -$567K
2021 Q3
1 quarter
TVTX icon
16
Travere Therapeutics
TVTX
$4.51B
$8.94M 1.63%
287,893
-18,622
-6% -$524K
2021 Q3
1 quarter
GTHX icon
17
DELISTED
G1 Therapeutics
GTHX
$8.75M 1.59%
856,798
-3,704
-0.4% -$47.2K
2019 Q4
8 quarters
EPZM
18
DELISTED
Epizyme
EPZM
$8.56M 1.56%
3,425,202
-547,628
-14% -$2.15M
2019 Q4
8 quarters
YMAB icon
19
DELISTED
Y-mAbs Therapeutics
YMAB
$7.24M 1.32%
446,457
-6,513
-1% -$139K
2019 Q4
8 quarters
GERN icon
20
Geron
GERN
$561M
$6.86M 1.25%
5,623,889
-108,881
-2% -$156K
2021 Q3
1 quarter
ADCT icon
21
ADC Therapeutics
ADCT
$180M
$6.82M 1.24%
337,396
-7,123
-2% -$172K
2020 Q2
6 quarters
VSTM icon
22
Verastem
VSTM
$798M
$6.71M 1.22%
272,628
+37,223
+16% +$1.17M
2021 Q3
1 quarter
HRMY icon
23
Harmony Biosciences
HRMY
$1.91B
$6.07M 1.11%
142,437
-9,213
-6% -$367K
2021 Q3
1 quarter
FOLD icon
24
DELISTED
Amicus Therapeutics
FOLD
$5.93M 1.08%
513,333
-33,225
-6% -$370K
2021 Q3
1 quarter
NEO icon
25
NeoGenomics
NEO
$1.92B
$4.79M 0.87%
140,422
-9,082
-6% -$356K
2021 Q3
1 quarter

Similar funds

MPM BioImpact's Q4 2021 Portfolio in Review

As of Q4 2021, MPM BioImpact held 35 positions worth $549M, down 15% from $645M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

MPM BioImpact's Q4 2021 filing shows 2 new, 2 increased, 22 reduced and 2 closed positions. Its largest new stake was Lite Strategy: 617,549 shares worth $33M. The largest sale was iTeos Therapeutics, an estimated $8.73M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 95% a quarter earlier.

  • MPM BioImpact's largest Q4 2021 buy was Lite Strategy: 617,549 shares worth $33M.
  • MPM BioImpact added most to Crinetics Pharmaceuticals in Q4 2021, an estimated $2.01M increase.
  • MPM BioImpact's biggest Q4 2021 reduction was iTeos Therapeutics, cutting an estimated $8.73M.
  • MPM BioImpact fully exited Lucira Health in Q4 2021, selling an estimated $4.39M.
  • MPM BioImpact's ten largest holdings make up 73% of its $549M portfolio in Q4 2021.
  • MPM BioImpact opened 2 new positions and closed 2 in Q4 2021.
  • MPM BioImpact's portfolio value fell 15% quarter-over-quarter to $549M.

Based on MPM BioImpact's 13F filing for Q4 2021, filed 11 Feb 2022.